Products
Pre-made Ranevetmab benchmark antibody ( Canine Whole mAb, anti-NGFB/NGF therapeutic antibody, Anti-HSAN5 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-469
Pre-Made Ranevetmab biosimilar, Canine Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ranevetmab is a caninized monoclonal antibody that can be potentially used in the treatment of Osteoarthritis (OA). Specific Inquiry.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-469-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-469-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-469-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-469-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Ranevetmab biosimilar, Canine Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody |
| INN Name | Ranevetmab |
| Target | NGF |
| Format | Canine Whole mAb |
| Derivation | Caninized |
| Species Reactivity | Canine |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Nexvet |
| Conditions Approved | na |
| Conditions Active | Osterarthritis |
| Conditions Discontinued | na |
| Development Tech | PETization Technology |
<